Feed / GPCR

Structure Therapeutics Inc.

GPCR

Healthcare · 49.14 -2.5% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Structure Therapeutics Inc.'s move is being confirmed by its market group.

GPCR accounts for 13.3% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveCounter-move#2 of 12 by movement share
Group movement share13.3%Absolute path energy—not portfolio weight
Relative path-3.00%counter
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

EWTX, AXSM, ALMS moved materially before GPCR. GPCR crossed its material path threshold at 15:05 ET, 1395 minutes after the first measured mover. PRAX, RCUS, MAZE followed.

EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind GPCR

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

WXILYFiling-linked namesupplierAug 6, 2025 ▾

“Our APIs and drug product for our product candidates are currently provided by a supplier, WuXi STA, a subsidiary of WuXi AppTec, and we expect to rely on this supplier for the foreseeable future.”

GILDGilead Sciences, Inc.competitorMay 7, 2026 ▾

“We are aware of GLP-1R small molecules in development by Eli Lilly, Qilu Regor Therapeutics, AstraZeneca/Eccogene, Jiangsu Hengrui Medicine, Huadong, Sciwind Biosciences, Ascletis, Gilead, Kallyope, MindRank, vTv Therapeutics, Carmot Therapeutics (acquired by…”

Depended on by

CRBPCorbus Pharmaceuticals HoldingscompetitorMar 9, 2026 ▾

“Additional competitors with different mechanisms of action, but are targeting weight loss by an oral drug include AstraZeneca PLC, Lilly, Novo Nordisk A/S, Structure Therapeutics Inc., and Viking Therapeutics, Inc., among others.”

Filing peers

VERUBIOAWVE

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 20 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

GPCR is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.